Expectations trend
FY2028 · fiscal year ending 2028-06-30 · fmp
NanoViricides Inc (NNVC)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$1.29-6.52%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.50 → 0.50 EPS · FY ending Jun 30, 2028 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for NNVC yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Generate measurable revenue | A primary condition in NanoViricides Inc's published investment case. The stated target is Revenue > $5 million. | Broken | Revenue remains at or near zero next 4 quarters | Revenue: $0 FY2026-Q4; GAAP. Published target: Revenue > $5 million. Target period is not explicitly aligned with this observation. Sep 28, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-06-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, speculative development-stage healthcare company, not an established earnings compounder. The long-term thesis is in a watch state: management continues to focus on NV-387, but the evidence of operating progress remains limited.
The snapshot provides no valuation measure or explicit account of market expectations, so whether NNVC is cheap or expensive versus peers is unclear. The available evidence points to a company still making losses and raising capital, rather than established commercial earnings.
Near term, losses and funding needs remain central: management has raised capital through offerings, while operating deficits continue despite some reduction in losses. NV-387 development is a multi-year opportunity, but the evidence gives no revenue data to gauge commercial progress; near-term results also carry elevated miss risk.
The multi-year thesis hinges on progress in developing and commercializing NV-387, alongside better control of operating losses and cash burn. In the near term, continued financing needs and the direction of healthcare-sector bellwethers are key swing factors; weaker sector results could remove a current tailwind.
Over the next 1 to 3 years, NNVC remains a high-risk development story with ongoing funding needs and limited proof of commercial progress. The long-term thesis depends on clinical development, loss management, and sector conditions. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in NanoViricides Inc's published investment case. The stated target is No new debt issuances beyond current agreements. |
| Under Pressure |
| New debt issuance announced within 12 months |
3 new equity issuances vs 0 new debt target Multiple 8-K filings confirm new securities purchase agreements and ATM sales agreements in 2025 and 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
EPS loss narrows toward zero | A primary condition in NanoViricides Inc's published investment case. The stated target is EPS loss improves to better than -$0.20. | Broken | EPS loss remains worse than -$0.35 in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.07 → $0.50 · observed estimates
$0.08B → $0.08B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-07-25 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-07-26 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-07-27 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-07-28 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-07-29 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-07-30 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-07-31 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-01 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-02 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-03 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-04 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-05 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-06 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-07 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-08 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-09 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-10 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-12 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-13 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-14 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-15 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-16 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-17 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-18 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-19 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-20 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-21 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-22 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-23 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-24 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-25 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-26 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-27 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-28 | $0.07 | $76,500,000 | 2 / 1 |
| 2026-08-29 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-08-30 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-08-31 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-01 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-02 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-03 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-04 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-05 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-06 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-07 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-08 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-09 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-10 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-11 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-12 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-13 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-14 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-15 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-16 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-17 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-18 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-19 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-20 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-21 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-22 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-23 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-24 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-25 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-26 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-27 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-28 | $0.50 | $76,500,000 | 2 / 1 |
| 2026-09-29 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-09-30 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-01 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-02 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-03 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-04 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-05 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-06 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-07 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-08 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-09 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-10 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-11 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-12 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-13 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-14 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-15 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-16 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-17 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-18 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-19 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-20 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-21 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-22 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-23 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-24 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-25 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-26 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-27 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-28 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-29 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-30 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-10-31 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-11-01 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-11-02 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-11-03 | $0.50 | $76,500,000 | 1 / 1 |
| 2026-11-04 | $0.50 | $76,500,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.